查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1848890

肺癌手術市場依手術方式、產品類型、癌症類型和最終用戶分類－2025-2032年全球預測

Lung Cancer Surgery Market by Approach, Product Type, Cancer Type, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，肺癌手術市場規模將達到 96.6 億美元，複合年成長率為 6.10%。

關鍵市場統計數據
基準年 2024 60.1億美元
預計年份：2025年 63.8億美元
預測年份 2032 96.6億美元
複合年成長率 (%) 6.10%

本書全面而實用地介紹了影響當代肺癌外科手術實踐的臨床創新、不斷發展的護理模式以及商業性因素。

肺癌手術正處於曲折點，臨床創新、護理模式的轉變以及不斷變化的報銷和貿易政策正在重塑臨床醫生和醫療系統提供治癒性和姑息性干預的方式。影像學、手術全期護理和手術平台的進步正穩步推動複雜切除術從高風險的開放式手術轉向低風險的手術方式，同時，行業整合和技術合作正在加速精密儀器在常規手術室中的應用。同時，全球供應鏈和關稅制度的變化正在改變醫院系統和門診手術中心的籌資策略、資本規劃和供應商選擇流程。

本執行摘要全面分析了臨床趨勢、技術應用動態、供應鏈敏感度以及相關人員的需求，旨在清楚揭示臨床實踐與商業機會的交匯點。該分析基於對外科醫生、醫院領導、醫療器材製造商和支付方的結構化一手調查，以及對醫療器材核准、臨床試驗終點和監管指南的嚴謹二手調查。其目標是提供戰術性決策，以及產品開發和上市的策略規劃。

讀者將從中獲得一種整合的視角，將設備層面的考慮與手術流程和最終用戶需求聯繫起來，重點關注機器人手術和胸腔鏡手術方式之間的相互作用、先進能量和縫合技術的作用，以及各種醫療環境下的操作要求。摘要優先提供清晰、可操作的觀點，以幫助多學科團隊將臨床目標與商業性現實相結合。

不斷發展的臨床流程、平台整合和分散式醫療服務如何重塑肺癌手術的流程實踐和商業策略

過去十年，肺癌手術領域發生了翻天覆地的變化，這主要得益於三大相互關聯的因素：不斷發展的臨床技術、平台主導的整合以及分散式醫療服務。微創手術已從小眾療法發展成為許多可切除腫瘤的主流選擇，這得益於影像技術、手術全期流程和外科醫生培訓計畫的改進。機器人輔助胸腔鏡平台和先進的胸腔鏡技術使得在解剖結構受限的區域進行更精準的手術操作成為可能，縮短了患者的恢復時間，並擴大了老年合併併發症患者的手術適應症。

同時，設備生態系統正朝著平台中心化發展，視覺化、能源和裝訂技術的設計旨在與系統結構無縫協作。這種整合減少了流程摩擦，縮短了學習曲線，同時也強化了圍繞生態系統鎖定和捆綁採購模式的競爭差異化。供應商正增加對軟體賦能功能的投資，例如增強視覺化、影像引導導航和流程分析，從而將價值延伸至硬體之外，並創造與耗材和服務合約相關的經常性收入來源。

門診手術中心參與的開胸切除術相對簡單，而醫院則專注於病情較危急的病例。這種分散化需要適應性強的設備和精簡的供應鏈來支持醫療服務點的多樣化。同時，培訓和認證計畫也在擴展，以滿足先進微創手術的技術要求，並強調模擬、指導和基於能力的評估。這些轉變正在重新定義醫療服務提供者和製造商的臨床工作流程、供應商談判和投資重點。

了解關稅變化將如何改變肺癌手術生態系統中的生產佈局、採購韌性和商業性優先事項。

將於2025年生效的關稅調整的累積影響將不僅限於關鍵採購成本，還將波及供應鏈、產品生命週期規劃和設備籌資策略。關稅調整將影響國內庫存水準、區域生產佈局和供應商選擇等方面的決策，促使醫療系統和製造商重新評估總到岸成本和採購彈性。對於高度專業化且集中於少數全球供應商的醫療設備和耗材而言，關稅帶來的成本壓力可能會加速大量定價、長期服務協議和本地庫存安排的談判。

製造商透過重組供應鏈架構來應對關稅環境，例如將生產轉移到低關稅區、建立本地組裝業務或重新設計零件以滿足在地採購閾值。這些因應措施會對產品供應計畫、零件物流以及資本設備交付週期的可預測性產生下游影響。對供應商而言，這意味著他們需要重新專注於採購的靈活性，包括採用多供應商籌資策略以及前置作業時間能夠抵禦跨境貿易波動的合約條款。

關稅帶來的成本壓力也將影響商業性優先事項，企業可能會將市場開發重點放在貿易環境穩定的地區，而在其他地區則選擇調整定價和服務模式。在臨床方面，一些醫院可能會推遲非緊急的資本購置，或優先考慮受跨境關稅波動影響較小的模組化投資。整體而言，關稅環境將改變肺癌外科手術生態系統的近期採購行為和長期策略投資選擇。

從深度、細分的觀點主導，將手術方法、器材類別、腫瘤組織學和醫療保健環境與採購和臨床應用動態連結。

細分市場分析揭示了不同手術方式、產品類型、癌症組織學類型和治療環境等因素對產品採納和採購的細微影響，這些因素都會影響臨床決策和商業性定位。在手術方式方面，微創手術和開放手術之間的差異尤其顯著。微創手術又分為機器人輔助胸腔鏡手術和視訊輔助胸腔鏡手術，其中機器人系統通常被定位為高階平台，整合了先進的視覺化技術和器械。機器人輔助胸腔鏡手術的典型特徵是成熟的機器人平台，這些平台提供整合的人體工學和手術分析功能；而視訊輔助胸腔鏡手術則分為多孔和單孔手術，這兩種手術方式側重於不同的器械配置和切口策略。這些差異會影響訓練需求、手術室設置和輔助設備的需求。

產品類型進一步加劇了競爭格局的細分，其中，入路裝置和套管針、內視鏡和視覺化系統、能量器械以及縫合器械各自在手術效率和安全性方面發揮著不同的作用。能量器械又分為先進的雙極電凝、電外科和超音波技術，每種技術在止血效果、組織損傷率和器械人體工學方面各有優劣。縫合器械分為手動縫合器和電動縫合器，電動縫合器可望在複雜角度下減輕外科醫師的操作難度，並提高縫合釘的一致性。這些產品層面的差異影響採購談判、資本預算和耗材合約。

按癌症類型進行細分也指南選擇手術方案和器械需求。非小細胞肺癌包括腺癌、大細胞癌和鱗狀細胞癌，每種癌症的典型腫瘤位置和切緣各不相同，這會影響手術方法和器械的選擇。小細胞肺癌獨特的生物學特性和治療模式通常需要整合腫瘤治療方案，以協調手術和全身性治療。最後，根據最終用戶（門診手術中心和醫院）進行細分，決定了醫院的營運限制：門診手術中心強調精簡的器械包和快速的周轉，而醫院則需要處理更廣泛的病例和複雜的手術全期護理。這些細分層次為整個生態系統中相關人員的市場策略、培訓投資和產品藍圖提供了資訊。

美洲、歐洲、中東和非洲以及亞太地區之間的異質性將如何驅動差異化的招募、監管策略和採購選擇？

區域動態正在影響肺癌外科領域的應用模式、監管重點和投資意願。在美洲，對技術賦能療法的重視以及高度集中的專業化醫療中心推動了對整合平台和高階耗材的需求，而醫保報銷體系和醫院整合則影響著採購窗口和採購流程的精細化程度。臨床網路和卓越中心（COE）模式促進了手術創新技術的快速推廣，同時也給供應商帶來了競爭壓力，要求其在療效和總醫療成本方面展現出明顯的價值。

歐洲、中東和非洲各國醫療保健系統和監管趨勢的差異導致了新技術應用時間的差異。西方市場傾向於透過結構化的衛生技術評估和集中採購來採納新的外科技術，而該地區的其他部分則可能優先考慮成本效益高的解決方案和本地製造夥伴關係關係。監管協調工作和跨國臨床合作通常會加速實證醫學證據的產生，但不同的報銷框架要求企業採取適應性強的商業性策略。

亞太地區是一個充滿活力的市場，既有巨大的臨床需求，又有快速發展的外科手術能力。不同市場成熟度的國家正在推行不同的策略。有些市場優先考慮快速採用機器人和胸腔外科系統，並輔以不斷擴大的外科培訓計畫；而有些市場則專注於可擴展、低成本的解決方案，以擴大醫療服務的覆蓋範圍。在每個地區，供應鏈的韌性、關稅的影響以及當地的臨床證據都在影響投資決策，並決定產品特性是否符合當地的手術量和醫療機構的能力。

策略性企業策略和差異化供應商模式，結合平台拓展、證據生成和供應彈性，能帶來競爭優勢。

主要企業正透過平台擴張、策略聯盟以及對先進視覺化、儀器連接和分析等實行技術的定向投資來鞏固自身地位。現有平台供應商持續投資於模組化和服務模式，以確保耗材收入，而新興競爭對手則專注於解決特定流程痛點或成本效益差距的利基創新。透過分銷合作、共同開發契約和臨床研究合作等方式開展企業間合作，仍是加速臨床檢驗和市場准入的熱門途徑。

供應商策略日益重視生命週期服務，例如培訓專案、監查和遠端監控能力，以減少實施摩擦並展現流程的一致性。投資於證據產生（例如臨床結果、比較療效試驗和真實世界數據收集）的公司在採購談判中更具優勢，因為醫療機構希望將技術支出與可衡量的品質改進聯繫起來。同時，在貿易和物流不確定性的情況下，維持產品供應促使企業最佳化製造和供應鏈，包括在組裝和擴大關鍵零件的供應商基礎。

競爭動態也反映了市場進入模式的多樣性。一些公司優先與大型醫療系統和綜合醫療服務網路直接合作，提供打包解決方案和長期服務協議。另一些公司則透過主導管道和成本最佳化的設備產品，瞄準門診手術中心和小型醫院。成功的公司能夠平衡臨床可靠性和營運靈活性，並根據高風險醫療中心和資源受限環境的需求，調整產品藍圖。

為領導者提供切實可行的優先建議，以協調臨床證據、供應鏈彈性、培訓基礎設施和適應性商業模式，從而實現永續推廣。

產業領導者必須採取多管齊下的策略，將臨床價值與供應鏈韌性和商業性靈活性結合。首先，投資可驗證的臨床證據和上市後研究，將設備性能與有意義的患者療效和營運指標聯繫起來。透過將技術應用與併發症、住院時間和手術時間的顯著減少掛鉤，相關人員可以更有力地論證基於價值的採購模式，並加速在醫院和門診環境中推廣應用。其次，考慮區域組裝和區域夥伴關係，以實現採購多元化，減輕關稅影響，並減少前置作業時間波動。這種方法可以保障服務的連續性，並穩定大量專案的耗材供應。

第三，優先建立一套訓練和能力框架，利用模擬、監考和基於能力的認證來縮短微創手術的推廣應用週期。完善的培訓計畫不僅能提高手術安全性，還能降低機構對資本投資的抗拒。第四，設計靈活的商業模式，以適應不同的臨床環境。提供模組化的資本選項、基於訂閱的耗材合約和配套服務包，以滿足不同終端用戶的預算和營運節奏。最後，促進與臨床醫生和支付方的合作，共同製定將外科手術干預與更廣泛的腫瘤治療方案相結合的路徑，確保設備創新能夠轉化為患者管理的整體改善。

一套嚴謹透明的研究框架，結合一手和二手研究，旨在提供可操作且有理有據的見解。

調查方法結合了系統性的原始資料收集、嚴謹的二手資料審查和三角驗證，以確保研究結果的可靠性和有效性。原始資料收集包括對來自不同地區和醫療機構的胸腔外科醫生、手術室主任、採購負責人和設備主管進行結構化訪談，並輔以現場觀察，以了解工作流程的限制因素和設備利用情況。這些調查重點關注手術決策因素、培訓需求、採購標準以及最終用戶對設備實際性能的感知。

二次審查納入了監管文件、臨床試驗註冊資訊、技術指導文件和同行評審文獻，以將主要研究結果置於更廣泛的依證中進行解讀。資料三角驗證法將訪談見解與已記錄的臨床結果和裝置註冊資訊進行匹配，以識別一致的模式並調和不同的觀點。透過有目的地進行細分，將研究結果按手術方法、產品類型、癌症組織學類型和最終用戶類別進行映射，從而能夠針對特定的臨床和商業性場景提出細緻的建議。

品質保證流程包括對調查方法審核、與獨立臨床顧問進行檢驗訪談，以及根據新出現的證據不斷完善結論。最終形成了一份穩健的綜合報告，該報告平衡了從業人員的經驗與已記錄的臨床和監管訊號，為決策者提供了可操作且有理有據的見解。

簡明扼要的結論，整合了臨床創新、營運要務和商業性考量，以指南肺癌手術的策略決策。

肺癌手術的發展軌跡反映了技術成熟度、實證醫學應用以及醫療服務模式轉變的融合，這些因素共同為製造商、醫療服務提供者和政策制定者帶來了巨大的機會和複雜的挑戰。向微創手術的轉變、設備生態系統的平台化以及部分手術量向門診轉移，都要求培訓、採購和產品開發等各個環節進行協調應對。同時，貿易政策的變化和關稅調整也要求我們密切注意供應鏈設計和商業性適應性。

將臨床證據融入營運計畫、拓展服務交付策略並投資於可擴展的培訓基礎設施的領導者，最能掌握臨床和商業性價值。在流程能力和系統相容性日益決定技術應用的當下，策略夥伴關係、有針對性的證據生成以及靈活的商業模式將使各機構脫穎而出。透過將技術創新與醫院和門診實踐的實際情況相結合，相關人員可以在保持業務績效的同時，改善患者預後。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 擴大使用機器人肺葉切除系統來最大程度地減少組織損傷並加速復原。
  • 推廣單孔胸腔鏡手術以減少術後疼痛和住院時間
  • 術中螢光影像技術在肺切除術中精確辨識腫瘤邊界
  • 應用人工智慧增強型CT分割工具對複雜肺腫瘤進行精確的術前規劃
  • 將ERAS通訊協定整合到手術流程中，以改善術後效果和病患滿意度。
  • 開發用於早期肺癌治療的微創支氣管鏡消融方法
  • 3D列印解剖模型在指導外科手術訓練和個別手術演練的應用日益廣泛

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 肺癌手術市場依手術方式分類

  • 微創
    • 機器人輔助胸腔手術（大鼠）
      • 達文西系統
    • 視訊輔助胸腔鏡手術（VAT）
      • 多門戶
      • 統一門戶
  • 開胸手術

9. 依產品類型分類的肺癌手術市場

  • 入路裝置及套管針
  • 內視鏡和視覺化系統
  • 能源設備
    • 先進的雙極元件
    • 電外科設備
    • 超音波能量裝置
  • 訂書機
    • 手動訂書機
    • 電動訂書機

第10章 依癌症類型分類的肺癌手術市場

  • 非小細胞肺癌
    • 腺癌
    • 大細胞癌
    • 鱗狀細胞癌
  • 小細胞肺癌

第11章 肺癌手術市場（依最終用戶分類）

  • 門診手術中心
  • 醫院

第12章 各地區肺癌手術市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 肺癌手術市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國肺癌手術市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Intuitive Surgical, Inc.
    • Medtronic plc
    • Johnson & Johnson
    • Stryker Corporation
    • Olympus Corporation
    • KARL STORZ SE & Co. KG
    • Becton Dickinson and Company
    • Boston Scientific Corporation
    • Smith & Nephew plc
    • Zimmer Biomet Holdings, Inc.
Product Code: MRR-501246436957

The Lung Cancer Surgery Market is projected to grow by USD 9.66 billion at a CAGR of 6.10% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 6.01 billion
Estimated Year [2025] USD 6.38 billion
Forecast Year [2032] USD 9.66 billion
CAGR (%) 6.10%

An integrated and actionable introduction that maps clinical innovation, care model evolution, and commercial forces shaping contemporary lung cancer surgical practice

Lung cancer surgery sits at an inflection point where clinical innovation, shifting care models, and evolving reimbursement and trade policy intersect to reshape how clinicians and health systems deliver curative and palliative interventions. Advances in imaging, perioperative care, and surgical platforms have steadily moved complex resections away from high-morbidity open thoracotomy toward lower-morbidity approaches, while industry consolidation and technology partnerships have accelerated the translation of precision tooling into everyday operating rooms. At the same time, changes in global supply chains and tariff regimes are altering procurement strategy, capital planning, and vendor selection processes for hospital systems and ambulatory surgical centers.

This executive summary synthesizes clinical trends, technology adoption dynamics, supply chain sensitivities, and stakeholder imperatives to give leaders a clear line of sight into where clinical practice and commercial opportunity converge. The analysis is grounded in structured primary research with surgeons, hospital leaders, device manufacturers, and payers, supplemented by rigorous secondary review of device approvals, clinical trial endpoints, and regulatory guidance. The goal is to provide practical insight that supports tactical decisions-equipment procurement, training investments, alliance formation-and strategic planning for product development and market entry.

Readers will find an integrated view that connects device-level considerations with procedural pathways and end-user needs, highlighting the interplay between robotic and thoracoscopic modalities, the role of advanced energy and stapling technologies, and the operational requirements of different care settings. The summary prioritizes clarity and actionable intelligence so that multidisciplinary teams can align clinical goals with commercial realities.

How clinical technique evolution, platform integration, and decentralized care delivery collectively redefine procedural practice and commercial strategies in lung cancer surgery

Over the last decade, the landscape of lung cancer surgery has undergone transformative shifts driven by three interlinked vectors: clinical technique evolution, platform-driven integration, and care delivery decentralization. Minimally invasive approaches have moved from niche alternatives to mainstream options for many resectable tumors, supported by improved imaging, perioperative pathways, and surgeon training programs. Robotic assisted thoracic platforms and refined thoracoscopic techniques have enabled more precise dissection in anatomically constrained fields, reducing recovery time and widening candidacy for surgery among older and comorbid patients.

At the same time, device ecosystems have become platform-centered, whereby visualization, energy, and stapling technologies are designed to function seamlessly within a system architecture. This integration reduces procedural friction and shortens learning curves, yet it also intensifies competitive differentiation around ecosystem lock-in and bundled procurement models. Suppliers increasingly invest in software-enabled capabilities-enhanced visualization, image-guided navigation, and procedural analytics-that extend value beyond hardware and create recurring revenue pathways tied to consumables and service agreements.

Care delivery has shifted toward a more distributed model, with ambulatory surgical centers participating in less complex thoracic resections and hospitals concentrating high-acuity cases. This decentralization requires adaptable instruments and streamlined supply chains that support site-of-care diversification. Concurrently, training and credentialing programs have expanded to accommodate the technical demands of advanced minimally invasive techniques, emphasizing simulation, proctorship, and competency-based assessment. Collectively, these shifts are redefining clinical workflows, supplier negotiations, and investment priorities for providers and manufacturers alike.

Understanding how tariff changes reshape manufacturing footprints, procurement resilience, and commercial priorities across the lung cancer surgical ecosystem

The cumulative impact of tariff changes announced for implementation in 2025 extends beyond headline procurement costs and reverberates across supply chains, product lifecycle planning, and device sourcing strategies. Tariff adjustments influence decisions around domestic inventory levels, regional manufacturing footprints, and supplier selection, prompting health systems and manufacturers to reassess total landed cost and procurement resilience. For devices and consumables that are highly specialized and concentrated among a limited set of global suppliers, tariff-induced cost pressure can accelerate negotiations on bundled pricing, long-term service contracts, and local stocking agreements.

Manufacturers respond to tariff environments by reshaping supply chain architecture-either by shifting production to lower-tariff jurisdictions, establishing local assembly operations, or redesigning components to meet local content thresholds. These responses have downstream effects on product availability timelines, replacement part logistics, and the predictability of capital equipment lead times. For providers, the result is a renewed focus on procurement agility, including multi-supplier sourcing strategies and contractual terms that protect against volatility in cross-border trade.

Tariff-driven cost pressures also influence commercial prioritization, where companies may choose to concentrate market development efforts in regions with stable trade terms while adapting pricing and service models in others. Clinically, some hospitals may defer non-urgent capital acquisitions or prioritize modular investments that are less exposed to cross-border tariff fluctuations. In aggregate, the tariff landscape reshapes both near-term purchasing behavior and long-term strategic investment choices across the lung cancer surgery ecosystem.

Deep segmentation-driven perspectives that link surgical approaches, device classes, tumor histologies, and care settings to procurement and clinical adoption dynamics

Segmentation insights reveal nuanced drivers of adoption and procurement across approaches, product types, cancer histologies, and care settings, each of which influences clinical decision-making and commercial positioning. Within the approach dimension, the contrast between minimally invasive and open surgery is pronounced: minimally invasive pathways split into robotic assisted thoracic surgery and video assisted thoracoscopic surgery, with robotic systems frequently positioned as premium platforms that bundle advanced visualization and instrument articulation. Robotic assisted thoracic surgery is represented by established robotic platforms that offer integrated ergonomics and procedural analytics, while video assisted thoracoscopic surgery differentiates into multiportal and uniportal techniques that prioritize different instrument profiles and incision strategies. These distinctions affect training needs, OR setup, and accessory demand.

Product typology further refines the competitive landscape, with access devices and trocars, endoscopes and visualization systems, energy devices, and stapling devices each playing distinct roles in procedural efficiency and safety. Energy modalities divide into advanced bipolar, electrosurgical, and ultrasonic technologies, each with trade-offs in hemostasis, tissue effect, and instrument ergonomics. Stapling solutions vary between manual and powered staplers, where powered stapling can reduce surgeon effort in difficult angles and potentially improve consistency in staple formation. These product-level differences shape procurement conversations, capital budgeting, and consumable contracts.

Cancer type segmentation also guides procedural selection and device requirements. Non-small cell lung cancer encompasses adenocarcinoma, large cell carcinoma, and squamous cell carcinoma, each with differing typical tumor locations and resection margins that influence the choice of approach and instrumentation. Small cell lung cancer, with its distinct biology and treatment paradigms, often prompts integrated oncologic planning where surgery is coordinated with systemic therapy. Finally, end-user segmentation-spanning ambulatory surgical centers and hospitals-dictates operational constraints, with ambulatory centers emphasizing streamlined instrument sets and rapid turnover while hospitals manage a broader case mix and complex perioperative care. Together, these segmentation layers inform go-to-market strategies, training investments, and product roadmaps for stakeholders across the ecosystem.

How regional heterogeneity across the Americas, Europe, Middle East and Africa, and Asia-Pacific drives differentiated adoption, regulatory strategy, and procurement choices

Regional dynamics shape adoption patterns, regulatory priorities, and investment appetite across the lung cancer surgery landscape. In the Americas, a strong emphasis on technology-enabled care and a high concentration of advanced specialty centers drive demand for integrated platforms and premium consumables, while reimbursement mechanisms and hospital consolidation influence purchasing windows and procurement sophistication. Clinical networks and center-of-excellence models here facilitate rapid dissemination of procedural innovations, yet they also create competitive pressure for suppliers to demonstrate clear value in outcomes and total cost of care.

In Europe, Middle East & Africa, variability across national health systems and regulatory pathways leads to heterogeneous adoption timelines. Western European markets tend to adopt new surgical technologies through structured health technology assessment and centralized procurement, whereas other parts of this region may prioritize cost-effective solutions and local manufacturing partnerships. Regulatory harmonization efforts and cross-border clinical collaborations often accelerate evidence generation, but differing reimbursement frameworks require adaptive commercial approaches.

Asia-Pacific presents a dynamic mix of high-volume clinical demand and rapidly evolving surgical capacity. Diverse market maturity across countries drives differentiated strategies: some markets prioritize rapid uptake of robotic and thoracoscopic systems supported by expanding surgical training programs, while others emphasize scalable, lower-cost solutions to broaden access. Across all regions, supply chain resilience, tariff exposure, and local clinical evidence shape investment decisions and the prioritization of product features that align with regional procedural volumes and provider capabilities.

Strategic corporate maneuvers and differentiated supplier models that combine platform expansion, evidence generation, and supply resilience to drive competitive advantage

Leading companies are consolidating their positions through platform expansion, strategic partnerships, and targeted investments in enabling technologies such as advanced visualization, instrument articulation, and analytics. Established platform providers continue to invest in modularity and service models that lock in consumable revenue, while emerging competitors focus on niche innovations that address specific procedural pain points or cost-efficiency gaps. Cross-company collaboration-through distribution partnerships, co-development agreements, and clinical research alliances-remains a common pathway to accelerate clinical validation and market entry.

Supplier strategies increasingly emphasize lifecycle services, including training programs, proctorship, and remote monitoring capabilities that reduce adoption friction and demonstrate procedural consistency. Companies that invest in evidence generation-clinical outcomes, comparative effectiveness studies, and real-world data collection-gain an advantage in procurement conversations where institutions seek to align technology spend with measurable quality improvements. At the same time, manufacturing and supply chain optimization, including localization of assembly and broadened supplier bases for critical components, have become central to maintaining product availability amid trade and logistical uncertainty.

Competitive dynamics also reflect varied go-to-market models. Some firms prioritize direct engagement with large health systems and integrated delivery networks, offering bundled solutions and long-term service agreements, while others target ambulatory surgical centers and smaller hospitals through distributor-led channels and cost-optimized device offerings. Successful companies balance clinical credibility with operational flexibility, aligning product roadmaps to both high-acuity centers and resource-constrained settings.

Practical and prioritized recommendations for leaders to align clinical evidence, supply resilience, training infrastructure, and adaptive commercial models for sustained adoption

Industry leaders must adopt a multi-pronged approach that aligns clinical value with supply chain resilience and commercial agility. First, invest in demonstrable clinical evidence and post-market surveillance that tie device performance to meaningful patient outcomes and operational metrics. By linking technology adoption to measurable reductions in complications, length of stay, and OR time, stakeholders can strengthen value-based procurement arguments and accelerate uptake across both hospitals and ambulatory settings. Second, diversify sourcing and consider regional assembly or localized partnerships to mitigate tariff exposure and reduce lead-time variability. This approach protects service continuity and stabilizes consumable supply for high-volume programs.

Third, prioritize training and competency frameworks that shorten the adoption curve for minimally invasive techniques, leveraging simulation, proctorship, and competency-based credentialing. Robust training programs not only increase procedural safety but also reduce institutional resistance to capital investments. Fourth, design flexible commercial models that reflect site-of-care differences; offer modular capital options, subscription-based consumable agreements, and bundled service packages that align with the budgets and operational rhythms of diverse end-users. Finally, foster collaborative relationships with clinicians and payers to co-develop pathways that integrate surgical interventions with broader oncology care plans, ensuring that device innovations translate into holistic improvements in patient management.

A rigorous and transparent research framework combining primary clinician engagement, secondary evidence review, and iterative triangulation to produce actionable and defensible insights

The research methodology blends systematic primary data collection with rigorous secondary review and triangulation to ensure reliability and relevance. Primary research comprised structured interviews with thoracic surgeons, OR directors, procurement leaders, and device executives across diverse geographies and care settings, supplemented by observational site visits to understand workflow constraints and instrument utilization. These engagements focused on procedural decision drivers, training needs, procurement criteria, and real-world device performance as perceived by end-users.

Secondary review incorporated regulatory filings, clinical trial registries, technology guidance documents, and peer-reviewed literature to contextualize primary findings within the broader evidence base. Data triangulation involved cross-checking interview insights against documented clinical outcomes and device registries to identify consistent patterns and reconcile divergent perspectives. Segmentation was applied deliberately to map findings across surgical approach, product type, cancer histology, and end-user categories, enabling granular recommendations tailored to specific clinical and commercial scenarios.

Quality assurance processes included methodological audits, validation interviews with neutral clinical advisors, and iterative refinement of conclusions based on emerging evidence. The result is a robust synthesis that balances practitioner experience with documented clinical and regulatory signals, producing insights that are both actionable and defensible for decision-makers.

A concise conclusion synthesizing clinical innovation, operational imperatives, and commercial considerations to guide strategic decision-making in lung cancer surgery

The trajectory of lung cancer surgery reflects a convergence of technological maturation, evidence-driven adoption, and shifting care delivery models that together create significant opportunities and complex challenges for manufacturers, providers, and policy-makers. The move toward minimally invasive approaches, the platformization of device ecosystems, and the decentralization of certain procedural volumes to ambulatory settings demand coordinated responses across training, procurement, and product development. Simultaneously, trade policy shifts and tariff adjustments require heightened attention to supply chain design and commercial adaptability.

Leaders who integrate clinical evidence with operational planning, diversify their supply strategies, and invest in scalable training infrastructures will be best positioned to capture clinical and commercial value. Strategic partnerships, targeted evidence generation, and flexible commercial models will differentiate organizations in a landscape where procedural capability and system compatibility increasingly determine adoption. By aligning technological innovation with the practical realities of hospital and ambulatory operations, stakeholders can improve patient outcomes while sustaining business performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing utilization of robot-assisted lobectomy systems to minimize tissue damage and accelerate recovery
  • 5.2. Expansion of single-incision thoracoscopic techniques to reduce postoperative pain and hospital stay
  • 5.3. Adoption of intraoperative fluorescence imaging for precise tumor margin identification during lung resections
  • 5.4. Implementation of AI-enhanced CT segmentation tools for accurate preoperative planning of complex lung tumors
  • 5.5. Integration of ERAS protocols in surgical workflows to improve postoperative outcomes and patient satisfaction
  • 5.6. Development of minimally invasive bronchoscopic ablation approaches for early-stage lung cancer management
  • 5.7. Rise of 3D printed anatomical models to guide surgical training and personalized procedure rehearsal

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Lung Cancer Surgery Market, by Approach

  • 8.1. Minimally Invasive
    • 8.1.1. Robotic Assisted Thoracic Surgery (Rats)
      • 8.1.1.1. Da Vinci Systems
    • 8.1.2. Video Assisted Thoracoscopic Surgery (Vats)
      • 8.1.2.1. Multiportal
      • 8.1.2.2. Uniportal
  • 8.2. Open Surgery

9. Lung Cancer Surgery Market, by Product Type

  • 9.1. Access Devices And Trocars
  • 9.2. Endoscopes And Visualization Systems
  • 9.3. Energy Devices
    • 9.3.1. Advanced Bipolar Devices
    • 9.3.2. Electrosurgical Devices
    • 9.3.3. Ultrasonic Energy Devices
  • 9.4. Stapling Devices
    • 9.4.1. Manual Staplers
    • 9.4.2. Powered Staplers

10. Lung Cancer Surgery Market, by Cancer Type

  • 10.1. Non Small Cell Lung Cancer
    • 10.1.1. Adenocarcinoma
    • 10.1.2. Large Cell Carcinoma
    • 10.1.3. Squamous Cell Carcinoma
  • 10.2. Small Cell Lung Cancer

11. Lung Cancer Surgery Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals

12. Lung Cancer Surgery Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Lung Cancer Surgery Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Lung Cancer Surgery Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Intuitive Surgical, Inc.
    • 15.3.2. Medtronic plc
    • 15.3.3. Johnson & Johnson
    • 15.3.4. Stryker Corporation
    • 15.3.5. Olympus Corporation
    • 15.3.6. KARL STORZ SE & Co. KG
    • 15.3.7. Becton Dickinson and Company
    • 15.3.8. Boston Scientific Corporation
    • 15.3.9. Smith & Nephew plc
    • 15.3.10. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LUNG CANCER SURGERY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. LUNG CANCER SURGERY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. LUNG CANCER SURGERY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. LUNG CANCER SURGERY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL LUNG CANCER SURGERY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL LUNG CANCER SURGERY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY DA VINCI SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY DA VINCI SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY DA VINCI SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY DA VINCI SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY DA VINCI SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY DA VINCI SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MULTIPORTAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MULTIPORTAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MULTIPORTAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MULTIPORTAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MULTIPORTAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MULTIPORTAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY UNIPORTAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY UNIPORTAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY UNIPORTAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY UNIPORTAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY UNIPORTAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY UNIPORTAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY OPEN SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY OPEN SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY OPEN SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY OPEN SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY OPEN SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY OPEN SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ACCESS DEVICES AND TROCARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ACCESS DEVICES AND TROCARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ACCESS DEVICES AND TROCARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ACCESS DEVICES AND TROCARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ACCESS DEVICES AND TROCARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ACCESS DEVICES AND TROCARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENDOSCOPES AND VISUALIZATION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENDOSCOPES AND VISUALIZATION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENDOSCOPES AND VISUALIZATION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENDOSCOPES AND VISUALIZATION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENDOSCOPES AND VISUALIZATION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENDOSCOPES AND VISUALIZATION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ADVANCED BIPOLAR DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ADVANCED BIPOLAR DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ADVANCED BIPOLAR DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ADVANCED BIPOLAR DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ADVANCED BIPOLAR DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ADVANCED BIPOLAR DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ELECTROSURGICAL DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ELECTROSURGICAL DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ELECTROSURGICAL DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ELECTROSURGICAL DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ELECTROSURGICAL DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ELECTROSURGICAL DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ULTRASONIC ENERGY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ULTRASONIC ENERGY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ULTRASONIC ENERGY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ULTRASONIC ENERGY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ULTRASONIC ENERGY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ULTRASONIC ENERGY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MANUAL STAPLERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MANUAL STAPLERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MANUAL STAPLERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MANUAL STAPLERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MANUAL STAPLERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MANUAL STAPLERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY POWERED STAPLERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY POWERED STAPLERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY POWERED STAPLERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY POWERED STAPLERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY POWERED STAPLERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY POWERED STAPLERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ADENOCARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ADENOCARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ADENOCARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ADENOCARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY LARGE CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY LARGE CELL CARCINOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY LARGE CELL CARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY LARGE CELL CARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY LARGE CELL CARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY LARGE CELL CARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY SMALL CELL LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY SMALL CELL LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY SMALL CELL LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2024 (USD MILLION)
  • TABLE 300. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 302. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 303. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2018-2024 (USD MILLION)
  • TABLE 304. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2025-2032 (USD MILLION)
  • TABLE 305. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2024 (USD MILLION)
  • TABLE 306. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2025-2032 (USD